Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jun;67(6):1404–1407. doi: 10.1038/bjc.1993.260

Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.

P Lissoni 1, S Barni 1, G Tancini 1, A Ardizzoia 1, F Rovelli 1, M Cazzaniga 1, F Brivio 1, A Piperno 1, R Aldeghi 1, D Fossati 1, et al.
PMCID: PMC1968531  PMID: 8512825

Abstract

The advanced tumours of the digestive tract are generally less responsive to conventional chemotherapies. Moreover, preliminary results with IL-2 immunotherapy also seem to show a low efficacy. On the basis of our previous studies suggesting s synergistic action between IL-2 and some neurohormones, such as the pineal indole MLT, a clinical trial was performed to investigate the clinical efficacy and tolerability of an immunotherapy with IL-2 plus MLT in patients with advanced neoplasms of the digestive tract. The study included 35 patients (colorectal cancer: 14; gastric cancer: 8; hepatocarcinoma: 6; pancreas adenocarcinoma: 7). Distant organ metastases were present in 31/35 patients. MLT was given orally at a daily dose of 50 mg at 8.00 p.m., starting 7 days before IL-2, which was given subcutaneously at a dose of 3 million IU/day at 8.00 p.m. for 6 days/week for 4 weeks, corresponding to one cycle of immunotherapy. In nonprogressed patients, a second cycle was given after a 21-day rest period. A complete response was achieved in two patients (gastric cancer: 1; hepatocarcinoma: 1). Six other patients obtained a partial response: (gastric cancer: 2; hepatocarcinoma: 2; colon cancer: 1; pancreas cancer: 1). Therefore, the overall response rate was 8/35 (23%). Stable disease was obtained in 11/35 (31%) patients, whereas the remaining 16 patients (46%) progressed. The response rate was significantly higher in untreated patients than in those previously treated with chemotherapy. Toxicity was low in all patients, who received the treatment as a home therapy. This study shows that the immunotherapy with low-dose IL-2 plus the pineal hormone MLT is a new well tolerated and effective therapy of advanced tumours of the digestive tract, mainly in gastric cancer and hepatocarcinoma.

Full text

PDF
1404

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atzpodien J., Körfer A., Evers P., Franks C. R., Knüver-Hopf J., Lopez-Hänninen E., Fischer M., Mohr H., Dallmann I., Hadam M. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother. 1990 Mar;2(1):18–26. [PubMed] [Google Scholar]
  2. Bartsch H., Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and times of administration. J Neural Transm. 1981;52(4):269–279. doi: 10.1007/BF01256752. [DOI] [PubMed] [Google Scholar]
  3. Dillman R. O., Oldham R. K., Tauer K. W., Orr D. W., Barth N. M., Blumenschein G., Arnold J., Birch R., West W. H. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991 Jul;9(7):1233–1240. doi: 10.1200/JCO.1991.9.7.1233. [DOI] [PubMed] [Google Scholar]
  4. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Lissoni P., Barni S., Crispino S., Tancini G., Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol. 1989 May;25(5):789–795. doi: 10.1016/0277-5379(89)90122-3. [DOI] [PubMed] [Google Scholar]
  6. Lissoni P., Tisi E., Barni S., Ardizzoia A., Rovelli F., Rescaldani R., Ballabio D., Benenti C., Angeli M., Tancini G. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer. 1992 Jul;66(1):155–158. doi: 10.1038/bjc.1992.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lissoni P., Tisi E., Brivio F., Ardizzoia A., Crispino S., Barni S., Tancini G., Conti A., Maestroni G. J. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents. 1991 Oct-Dec;5(4):154–156. [PubMed] [Google Scholar]
  8. Maestroni G. J., Conti A., Pierpaoli W. Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonizes the immunosuppressive effect of corticosterone. J Neuroimmunol. 1986 Nov;13(1):19–30. doi: 10.1016/0165-5728(86)90047-0. [DOI] [PubMed] [Google Scholar]
  9. Mathews P. M., Froelich C. J., Sibbitt W. L., Jr, Bankhurst A. D. Enhancement of natural cytotoxicity by beta-endorphin. J Immunol. 1983 Apr;130(4):1658–1662. [PubMed] [Google Scholar]
  10. Ritchie A. W., Oswald I., Micklem H. S., Boyd J. E., Elton R. A., Jazwinska E., James K. Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) 1983 Jun 4;286(6380):1773–1775. doi: 10.1136/bmj.286.6380.1773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES